Company: BIAF
Filing Date: 2025-06-02
Form Type: DEF 14A
Source: 0001641172-25-013280
Chunk: 3

Company: bioAffinity Technologies, Inc.
Filing Date: 2025-06-02
Form: DEF 14A
Chunk 3
---
0 Nacogdoches Road, Suite 216

San Antonio, Texas 78217

PROXY STATEMENT

FOR THE ANNUAL MEETING OF STOCKHOLDERS TO BE HELD ON JULY 25, 2025

GENERAL INFORMATION</div>

The Board of Directors (the “Board”)
of bioAffinity Technologies, Inc., a Delaware corporation (the “Company”), is soliciting proxies to be used
at the 2025 Annual Meeting of Stockholders to be held on Friday, July 25, 2025, at 8:00 a.m. Central Time (the “Annual Meeting”)
at the Company’s principal office at 3300 Nacogdoches Road, Suite 216, San Antonio, Texas 78217. This proxy statement (this “Proxy Statement”) and the 2024 Annual Report to Stockholders, which is not a part of our proxy solicitation materials, are posted
on the internet at www.proxyvote.com, and the Notice of Internet Availability of Proxy Materials (the “Notice”)
will be mailed to our stockholders on or about June 2, 2025. If you previously requested electronic or paper delivery of the proxy
materials, you will be sent this Proxy Statement, the accompanying proxy card, and the 2024 Annual Report to Stockholders on or about
June 2, 2025.

Voting Matters and the Board’s Recommendation

| Agenda Item                                                                                                                                       
 Election                                                                                                                                          
 of seven directors                                                                                                                                
 Ratification of WithumSmith+Brown, PC as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2025 |     | Board Vote                
 Recommendation            
 FOR each Director Nominee 
 FOR                       |     | Page Reference 
             10 
             12 |
|:--------------------------------------------------------------------------------------------------------------------------------------------------|:----|:--------------------------|:----|---------------:|
| Approval                                                                                                                                          
 of a reverse stock split with respect to the Company’s issued and outstanding shares of common stock, par value $0.007 per                        
 share (“Common Stock”), at a ratio of 1-for-2 to 1-for-100 (the “Reverse Stock Split                                                              
 Proposal”)                                                                                                                                        |     | FOR                       |     |             16 |
| Approval                                                                                                                                          
 of the issuance of up to an aggregate of 2,926,166 shares of our Common Stock upon the exercise of our Common Stock                               
 purchase warrants issued in connection with our private placement offering that closed on February 26